Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Lidak Pharm. [LDAKA] -- Ignore unavailable to you. Want to Upgrade?

To: telebob who wrote (753)	12/31/1997 4:40:00 PM
From: Red Dragon	Read Replies (1) \| Respond to of 1115

Looks pretty bad. If I were to guess, I would say that Bristol Myers had access to the recent phase III trial results and decided to dump this dog. I think that all those who pointed out concerns about the vague "positive" phase 3 results are ultimately going to be correct. It wouldn't surprise me if the FDA does NOT approve Lidakol for use based on the fact that the drug is not significantly different from placebo. I think there is a reason that Lidak did not announce results of their drug compared with placebo . Remember, Lidakol was no better than placebo in prior trials as well. News came after the market close. Like many others on this thread, I've held shares in this dog for years based on recommendations from the newsletter BI research, and I'm going to throw in the towel and take my (big) loss.